Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

ontinuous release formulation of omega interferon with the Omega DUROS device may improve the treatment of HCV by offering a more convenient, potentially safer and more efficacious therapy for HCV patients."

About Omega DUROS Therapy

Omega DUROS therapy is being developed to improve the treatment of HCV by offering a more convenient and potentially safer and more effective treatment. Omega DUROS therapy is designed to deliver a continuous and consistent dose of omega interferon for three months via the implantable DUROS device, a drug delivery technology developed by ALZA Corporation, and licensed to Intarcia for use in certain broad fields. Another product incorporating the DUROS technology has already been approved by the FDA for the palliative treatment of prostate cancer. Intarcia is also leveraging the DUROS technology in evaluating other drug development opportunities. The most advanced of these is focused on the delivery of GLP-1 and GLP-1 analogs with the DUROS device for the treatment of type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia's drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. The initial programs that Intarcia is pursuing are in hepatitis C and type 2 diabetes.

About Hepatitis C

Hepatitis C is a major global public health problem. According to the World Health Organization, more than 170 million people worldwide are chronically infected with HCV, and three to four million new HCV infections occur annually. The U.S. Centers for Disease Control and Prevention has estimated that in the United States approximately 3.2 million people are chronically infected with HCV and approximately 25,00
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:7/29/2014)... TAMPA, Fla. , July, 29  2014 ... it has hired John Bournas as ... who announced plans to leave the Society last ... with extensive competencies in the healthcare association industry ... to the Society a clear vision for the ...
(Date:7/29/2014)... LAUDERDALE, Fla. , July 29, 2014 /PRNewswire-iReach/ ... medical service provider, has launched its Medical ... Program.  These services are tailored to the ... excellent standards prompted industry operators to propose that ... MHG Medical,s new program is intended to ...
(Date:7/29/2014)... 29, 2014 According to a ... Trauma Fixation Devices Market - Global Forecast, Market Share, ... global orthopedic trauma fixation devices market is estimated at ... grow at a CAGR of 7.2% from 2014 to ... billion in 2020. Browse the Orthopedic Trauma ...
Breaking Medicine Technology:ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4
... 2007 /PRNewswire-USNewswire/ -- The,following statement may be attributed ... Medical Research (CAMR): , "In the face of ... the stroke of his veto pen deliberately to ... well as endanger,the future health and well being ...
... - Elixir,Pharmaceuticals, Inc., announced today the publication ... (mitiglinide calcium,hydrate) monotherapy, or combination therapy with ... meals. The data were,published in the Abstract ... Scientific Sessions in Chicago, Illinois.,Glufast is an ...
Cached Medicine Technology:President Bush Ignores America's Plea for Support of Stem Cell,Research 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5
(Date:7/29/2014)... the nation,s largest interdisciplinary organization devoted to ... Bowers, PhD, RN, FAAN, of the University of Wisconsin-Madison ... Minority Issues in Gerontology Outstanding Mentorship Award. , This ... has exemplified outstanding commitment and dedication to mentoring minority ... presentation will take place at GSA,s 67th Annual Scientific ...
(Date:7/29/2014)... the nation,s largest interdisciplinary organization devoted to the ... PhD, of Cornell University as the 2014 recipient of ... in Behavioral and Social Gerontology. , This distinguished honor, ... and social gerontology. Individuals who have received their doctorate ... is given by GSA in conjunction with the Margret ...
(Date:7/29/2014)... The report “Filling Equipment Market by Industry (Food, ... Weight), Process (Manual, Semi-Automatic, Automatic), Product (Solid, Semi-Solid, ... to 2019”, defines the filling equipment market and ... segments with analyses and projections of the market ... of value. It also identifies the driving and ...
(Date:7/29/2014)... ENCINITAS, Calif. (PRWEB) July 29, 2014 ... prescription drug abuse directly at the source? That’s the ... , an innovative prescription drug abuse risk program developed ... from hundreds of applicants worldwide to be part of ... September 10-12 in San Francisco, CA. The Hive is ...
(Date:7/29/2014)... INDIANAPOLIS -- With the increasing use of electronic ... a growing demand for a computerized version of ... United States. In a new study, researchers from ... Regenstrief Institute report that substantial work lies ahead ... Future,s guidelines into computerized prompts for physicians, but ...
Breaking Medicine News(10 mins):Health News:Bowers to receive GSA's 2014 Minority Mentorship Award 2Health News:Löckenhoff earns GSA's 2014 Baltes Foundation Award 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 3Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 4Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 2Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 3Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 2Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 3
... chronically exposed to family turmoil, violence, noise, poor housing ... strain// than other young people. ,However, when ... these negative physiological changes, reports a new study from ... that the cardiovascular systems of youths who are exposed ...
... cancer is so much more prevalent in men than women: ... in men than women plays a role in the development ... new types of treatment with the disease. ,In ... Chawnshang Chang, Ph.D., of the University of Rochester Medical Center ...
... stent therapy and bypass surgery for coronary artery disease ... event within 30 days after the procedures// , according ... similar outcomes three years after treatment. Patients with coronary ... bypass surgery to reroute the arteries' blood flow or ...
... the carotid artery by dental x-rays is not enough evidence ... a review published in the Journal of the American Dental ... leading causes of death and disability among adults in the ... and nutrients to the brain bursts or becomes clogged by ...
... head and neck cancer that targets multiple peptides (parts ... tumors. ,The researchers created the vaccine ... is mutated in most cancers and associated with poor ... also expresses unaltered, or "wild-type," p53 peptides in tumors. ...
... a dermatologist has a higher survival rate than by a ... to detect// the tumor in its early stages which can ... ,Individuals whose melanoma is diagnosed by a dermatologist may be ... years than those with melanoma diagnosed by a non-dermatologist, according ...
Cached Medicine News:Health News:Adolescents Exposed to Family Turmoil and Violence Face Stress-related Problems 2Health News:Scientists Find Clue for the Prevalence of Bladder Cancer More in Men 2Health News:Scientists Find Clue for the Prevalence of Bladder Cancer More in Men 3Health News:Scientists Find Clue for the Prevalence of Bladder Cancer More in Men 4Health News:Bypass Surgery, Drug-eluting Stents Possess Similar Risk and Outcome 2Health News:Dental X-rays of Carotid Artery Cannot Estimate Stroke Risk 2Health News:Head and Neck Cancer Vaccine Targets Proteins to Create Immune Response 2Health News:Chances of Survival for Melanoma is High When Detected by Dermatologists 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: